CoChat
Sign Up
Cited by 50Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus

González-Ortiz, Manuel, Guerrero-Romero, Jesús F., Violante-Ortiz, Rafael, Wacher-Rodarte, Niels, Martínez-Abundis, Esperanza, Aguilar-Salinas, Carlos, Islas-Andrade, Sergio, Arechavaleta-Granell, Rosario +7 more·2009·Journal of Diabetes and its Complications
DOI 10.1016/j.jdiacomp.2008.09.002
Open this paper in CoChat — free account

Abstract

Aim The aim of this study was to compare the efficacy of glimepiride/metformin combination versus glibenclamide/metformin for reaching glycemic control in patients with uncontrolled type 2 diabetes mellitus.Patients and methods A randomized, double-blind, multicenter clinical trial was performed in 152 uncontrolled type 2 diabetic patients. Serum fasting and postprandial glucose, hemoglobin A1c (A1C), high-density lipoprotein cholesterol, and triglycerides were measured. After random allocation, all patients received two pills of glimepiride (1 mg)/metformin (500 mg) or glibenclamide (5 mg)/metformin (500 mg) po once a day. Dosage was increased to a maximum of four pills in order to reach the glycemic control goals (fasting glucose <or=7.2 mmol/l, postprandial glucose <10.0 mmol/l, A1C <7%, or an A1C >or=1% reduction). Statistical analyses were carried out using chi-square, ANOVA, or Student's t test. The protocol was approved by an ethics committee and met all requirements needed to perform research in human subjects; all patients gave written informed consent.Results Each study group included 76 patients. No significant differences in basal clinical and laboratory characteristics between groups were found. At the end of the study, A1C concentration was significantly lower in the glimepiride/metformin group (P=.025). A higher proportion of patients from the glimepiride group (44.6% vs. 26.8%, P<.05) reached the goal of A1C <7% at 12 months of treatment. A higher proportion of hypoglycemic events were observed in the glibenclamide group (28.9% vs. 17.1%, P<.047).Conclusion Glimepiride/metformin demonstrated being more efficacious than glibenclamide/metformin at reaching the glycemic control goals with less hypoglycemic events in patients with uncontrolled type 2 diabetes mellitus.

Integrity signals

Registry

Crossref · 10.1016/j.jdiacomp.2008.09.002

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The glimepiride/metformin combination results in lower HbA1c and fewer hypoglycemic events compared to the glibenclamide/metformin combination.

    “The glimepiride/metformin combination results in a lower HbA1c concentration and fewer hypoglycemic events when compared to the glibenclamide/metformin combination [25].”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [25]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
González-Ortiz, M., Guerrero-Romero, J. F., Violante-Ortiz, R., Wacher-Rodarte, N., Martínez-Abundis, E., Aguilar-Salinas, C., Islas-Andrade, S., Arechavaleta-Granell, R., González-Canudas, J., Rodríguez-Morán, M., Zavala-Suárez, E., Ramos-Zavala, M. G., Metha, R., Revilla-Monsalve, C., & Beltrán-Jaramillo, T. J.
Affiliations
  • Mexican Social Security Institute (MX)
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
ORCID
Venue
Journal of Diabetes and its Complications
Publisher
Elsevier BV
Published
2009-11
Volume
23
Issue
6
Pages
376-379
ISSN
  • 0891-6632 (ISSN-L)
  • 1056-8727
DOI
10.1016/j.jdiacomp.2008.09.002
OpenAlex
W2113355164
Cited by
50
References
14
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 5
FWCI
1.93
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Diabetes and its Complications (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, glimepiride, glibenclamide, metformin, combination therapy, glycemic control, HbA1c, hypoglycemia, sulfonylureas, uncontrolled diabetes
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Drug Combinations, Female, Glyburide, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Body Mass Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review